Afficher la couverture 'Real life experience of mycophenolate mofetil monotherapy in liver transplant patients | Lassailly, Guillaume' en grand format
/5

0 avis

Real life experience of mycophenolate mofetil monotherapy in liver transplant patients

Archive ouverte

Lassailly, Guillaume | Dumortier, Jerome | Saint-Marcoux, Franck | El Amrani, Mehdi | Boulanger, Juliette | Boleslawski, Emmanuel | Millet, Guillaume | Ningarhari, Massih | Truant, Stéphanie | Canva, Valerie | Goria, Odile | Boillot, Olivier | Louvet, Alexandre | Mathurin, Philippe | Lebuffe, Gilles | Pruvot, Francois-Rene | Marquet, Pierre | Dharancy, Sebastien

Edité par CCSD ; Elsevier -

International audience. BACKGROUND: Mycophenolate mofetil (MMF) monotherapy following liver transplantation (LT) remains controversial due to a risk of acute rejection. The aim of this study was to report the largest multicenter experience of the use a MMF monotherapy guided by therapeutic drug monitoring using pharmacoslope modeling and Bayesian estimations of the MPA inter-dose AUC (BEMPAMETHODS: MMF daily doses were adjusted to reach the BEMPARESULTS: From 2000-2014, in 2 transplantation centers, 94 liver transplant recipients received MMF monotherapy 6.5±4 years after LT. The mean BEMPACONCLUSIONS: MMF monotherapy regimen appears usually safe and beneficial, with low risk of acute rejection and eGFR improvement. Therapeutic drug monitoring strategy seemed useful by identifying 14% of patients with low MMF exposure.

Suggestions

Du même auteur

Trans-catheter aortic valve replacement (tavr) as bridge therapy restoring eligibility for liver transplantation in cirrhotic patients

Archive ouverte | Levy, Clementine | CCSD

International audience. Severe aortic stenosis is a widespread valve disease, constituting a contraindication to organ transplantation due to cardiovascular morbidity and projected mortality. Mortality after convent...

Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation

Archive ouverte | Minoux, Kate | CCSD

International audience. Data on efficacy and safety of sorafenib in a neoadjuvant setting for HCC awaiting liver transplantation (LT) are heterogeneous and scarce. We aimed to investigate the trajectory of patients ...

Morbid obesity increases death and dropout from the liver transplantation waiting list: A prospective cohort study

Archive ouverte | Delacôte, Claire | CCSD

International audience. Abstract Liver transplant (LT) candidates with a body mass index (BMI) over 40 kg/m 2 have lower access to a liver graft without clear explanation. Thus, we studied the impact of obesity on t...

Chargement des enrichissements...